176 related articles for article (PubMed ID: 37433264)
1. Fibrin-associated large B-cell lymphoma shows frequent mutations related to immune surveillance and PTEN.
Boyer DF; Perry A; Wey E; Hsueh J; Li A; Jackson R; Soma L; Zhang W; Song JY
Blood; 2023 Sep; 142(11):1022-1025. PubMed ID: 37433264
[No Abstract] [Full Text] [Related]
2. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.
Abubaker J; Bavi PP; Al-Harbi S; Siraj AK; Al-Dayel F; Uddin S; Al-Kuraya K
Leukemia; 2007 Nov; 21(11):2368-70. PubMed ID: 17657213
[No Abstract] [Full Text] [Related]
4. Effects of microRNA-21 on apoptosis by regulating the expression of PTEN in diffuse large B-cell lymphoma.
Song J; Shao Q; Li C; Liu H; Li J; Wang Y; Song W; Li L; Wang G; Shao Z; Fu R
Medicine (Baltimore); 2017 Sep; 96(39):e7952. PubMed ID: 28953617
[TBL] [Abstract][Full Text] [Related]
5. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
Lemma SA; Kuusisto M; Haapasaari KM; Sormunen R; Lehtinen T; Klaavuniemi T; Eray M; Jantunen E; Soini Y; Vasala K; Böhm J; Salokorpi N; Koivunen P; Karihtala P; Vuoristo J; Turpeenniemi-Hujanen T; Kuittinen O
Carcinogenesis; 2017 Aug; 38(8):812-820. PubMed ID: 28854563
[TBL] [Abstract][Full Text] [Related]
6. Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
Zheng S; Ma J; Li J; Pang X; Ma M; Ma Z; Cui W
Hum Immunol; 2023 Oct; 84(10):551-560. PubMed ID: 37481380
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma.
Pfeifer M; Lenz G
Cell Cycle; 2013 Nov; 12(21):3347-8. PubMed ID: 24091535
[No Abstract] [Full Text] [Related]
8. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
10. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.
Liu YY; Yao SN; Zhao Y; Yao ZH; Ma J; Xia QX; Fu K; Yang SJ
Leuk Lymphoma; 2010 Sep; 51(9):1692-8. PubMed ID: 20807096
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
[TBL] [Abstract][Full Text] [Related]
12. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
[TBL] [Abstract][Full Text] [Related]
13. The High Expression of the microRNA 17-92 Cluster and its Paralogs, and the Downregulation of the Target Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression.
Battistella M; Romero M; Castro-Vega LJ; Gapihan G; Bouhidel F; Bagot M; Feugeas JP; Janin A
J Invest Dermatol; 2015 Jun; 135(6):1659-1667. PubMed ID: 25634356
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
15. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma.
Nakahara Y; Nagai H; Kinoshita T; Uchida T; Hatano S; Murate T; Saito H
Leukemia; 1998 Aug; 12(8):1277-80. PubMed ID: 9697884
[TBL] [Abstract][Full Text] [Related]
17. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
[TBL] [Abstract][Full Text] [Related]
18. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
19. [Expression of MiRNA-21 in diffuse large B cell lymphoma and its significance].
Song GQ; Gu L; He BS; Pan YQ; Wang SK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1603-9. PubMed ID: 25543482
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.
He W; Xu Z; Song D; Zhang H; Li B; Gao L; Zhang Y; Feng Q; Yu D; Hu L; Chen G; Tao Y; Wu X; Shi J; Zhu W
Life Sci; 2020 Feb; 243():117249. PubMed ID: 31926247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
